Why did Laurus Labs (LAURUSLABS) stock move recently?

On 7/27/2026, Laurus Labs moved +7.0% — Laurus Labs rose on strong Q1 FY27 results (net profit +126%, revenue +29%) driven by CDMO revenue surge of ~67-69% and improved margins, which triggered multiple brokerage upgrades and bullish commentary. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Laurus Labs (LAURUSLABS) overvalued or fairly valued?

MarketChacha shows Laurus Labs's valuation in context — a forward P/E of about 69.0, a price-to-book of about 21.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Laurus Labs's revenue?

Laurus Labs reported revenue of ₹6,089 Cr for FY2026, with net profit of ₹740 Cr, per official filings.

What is the share price of Laurus Labs (LAURUSLABS)?

Laurus Labs last traded at ₹2,069.00 (+0.4% on the day), as of 10/19/2026 — a delayed quote shown for education, not investment advice.

Laurus Labs

LAURUSLABS · NSE · Pharma · India

Snapshot

TickerLAURUSLABS

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees7,059

HeadquartersHyderabad, India

Websitewww.lauruslabs.com

Filings tracked9

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Who owns it

Promoters32.0%
Institutions33.6%
Public & other34.4%

158 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend13.1% → 13.0%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 3% · PAT 3%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹2,047 Cr · EPS 5.86

Est. earnings growth +26.0%

Next fiscal year

Rev ₹9,672 Cr · EPS 29.99

Est. earnings growth +18.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹6,813 Cr

Net margin

13.0%

Revenue CAGR (3y)

+4.1%

Profit CAGR (3y)

+4.0%

Net profit (FY2026)

₹889 Cr

Ask MarketChacha about LAURUSLABS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 27, 2026
Laurus Labs rose on strong Q1 FY27 results (net profit +126%, revenue +29%) driven by CDMO revenue surge of ~67-69% and improved margins, which triggered multiple brokerage upgrades and bullish commentary.
source 1 ↗source 2 ↗source 3 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹6,813 Cr	₹889 Cr	13.0%
FY2025	₹5,554 Cr	₹358 Cr	6.5%
FY2024	₹5,041 Cr	₹161 Cr	3.2%
FY2023	₹6,041 Cr	₹790 Cr	13.1%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
Q1 FY27	₹1,757 Cr	₹290 Cr	5.37	16.5%
Q4 FY26	₹1,812 Cr	₹279 Cr	—	15.4%
Q3 FY26	₹1,778 Cr	₹252 Cr	—	14.2%
Q2 FY26	₹1,653 Cr	₹195 Cr	—	11.8%
Q1 FY26	₹1,570 Cr	₹163 Cr	—	10.4%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Investor Presentation
Please see attached enclosure.
BSE9/18/2026
Earnings Call Transcript
Please see annexed enclosure.
BSE7/30/2026
Allotment of ESOP / ESPS
Please see annexed enclosure.
BSE7/27/2026
Update On Composite Scheme Of Arrangement
Please see annexed enclosure.
BSE7/25/2026
Press Release / Media Release
Please see annexed enclosure
BSE7/24/2026
Investor Presentation
Please see enclosed annexure
BSE7/24/2026
Change in Directorate
Please see enclosed annexure
BSE7/24/2026
Board Meeting Outcome for Outcome Of Board Meeting
Please see enclosed annexure
BSE7/24/2026
Results - Financial Results For Quarter Ended 30.06.2026
Please see annexed enclosure
BSE7/24/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.